Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Tarsus Pharmaceuticals, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | 3.4% | 3.6% | 0.4% | 0.1% | 0.1% | 0.0% |
| Gross profit | | | 96.6% | 96.4% | 99.6% | 99.9% | 99.9% | 100.0% |
| Research and development | | | 251.5% | 229.6% | 155.5% | 73.1% | 72.8% | 70.4% |
| General and administrative | | | 229.6% | 182.6% | 116.8% | 44.5% | 39.7% | 32.5% |
| EBITDA | | | -382.8% | -314.1% | -174.5% | -20.8% | -15.7% | -6.1% |
| Depreciation | | | 1.7% | 1.5% | 1.2% | 0.5% | 0.6% | 0.5% |
| EBIT | | | -384.4% | -315.6% | -175.7% | -21.3% | -16.2% | -6.5% |
| Pre-tax income | | | -391.7% | -322.7% | -182.6% | -24.1% | -18.4% | -9.4% |
| Income taxes | | | 0.4% | 2.3% | 1.5% | 0.1% | 0.0% | -0.6% |
| Net income | | | -392.1% | -325.0% | -184.1% | -24.2% | -18.4% | -8.8% |
|